A Review of the Clinical Pharmacokinetics of Polymyxin B

被引：102

作者：

Avedissian, Sean N. ^{[1
,2
,3
]}

Liu, Jiajun ^{[1
,2
,3
]}

Rhodes, Nathaniel J. ^{[1
,2
,3
]}

Lee, Andrew ^{[4
,5
]}

Pais, Gwendolyn M. ^{[1
,2
]}

Hauser, Alan R. ^{[6
,7
]}

Scheetz, Marc H. ^{[1
,2
,3
,8
]}

机构：

[1] Midwestern Univ, Chicago Coll Pharm, Dept Pharm Practice, Downers Grove, IL 60515 USA

[2] Midwestern Univ, Pharmacometr Ctr Excellence, Downers Grove, IL 60515 USA

[3] Northwestern Mem Hosp, Dept Pharmacol, Chicago, IL 60611 USA

[4] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA

[5] Northwestern Univ, Dept Biol Engn, Evanston, IL 60208 USA

[6] Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA

[7] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA

[8] Midwestern Univ, Dept Pharmacol, Coll Grad Studies, Downers Grove, IL 60515 USA

来源：

ANTIBIOTICS-BASEL | 2019年 / 8卷 / 01期

关键词：

polymyxin B; pharmacokinetics; MASS-SPECTROMETRY METHOD; SOLID-PHASE EXTRACTION; HUMAN PLASMA; COLISTIN; VALIDATION; ASSAY; QUANTIFICATION; COLISTIMETHATE; NEPHROTOXICITY; DISPOSITION;

D O I：

10.3390/antibiotics8010031

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer therapies are becoming available, it is anticipated that resistance to these agents will continue to emerge, and understanding the safest and most efficacious manner to deliver polymyxin B will remain highly important. Recent data have demonstrated that polymyxin B may be less nephrotoxic than colistin. Pharmacokinetically, polymyxin B is primarily eliminated via non-renal pathways, and most do not recommend adjusting the dose for renal impairment. However, some recent studies suggest a weak relationship between polymyxin B clearance and patient creatinine clearance. This review article will describe the clinical pharmacokinetics of polymyxin B and address relevant issues in chemistry and assays available.

引用

页数：11

共 51 条

[1] Uptake of Polymyxin B into Renal Cells [J].

Abdelraouf, Kamilia ;

Chang, Kai-Tai ;

Yin, Taijun ;

Hu, Ming ;

Tam, Vincent H. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (07) :4200-4202

[2] Pharmacokinetics and Renal Disposition of Polymyxin B in an Animal Model [J].

Abdelraouf, Kamilia ;

He, Jie ;

Ledesma, Kimberly R. ;

Hu, Ming ;

Tam, Vincent H. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (11) :5724-5727

[3] Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients [J].

Avedissian, Sean N. ;

Miglis, Cristina ;

Kubin, Christine J. ;

Rhodes, Nathaniel J. ;

Yin, Michael T. ;

Cremers, Serge ;

Prickett, Michelle ;

Scheetz, Marc H. .

PHARMACOTHERAPY, 2018, 38 (07) :730-738

[4]

BAINES RD, 1964, JAMA-J AM MED ASSOC, V190, P278

[5] SODIUM SULPHOMETHYL DERIVATIVES OF POLYMYXINS [J].

BARNETT, M ;

BUSHBY, SRM ;

WILKINSON, S .

BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1964, 23 (03) :552-+

[6]

Bedford Laboratories, 2011, POL B

[7]

Beringer P, 2001, Curr Opin Pulm Med, V7, P434, DOI 10.1097/00063198-200111000-00013

[8] Polymyxin B versus colistin: an update [J].

Cai, Yiying ;

Lee, Winnie ;

Kwa, Andrea L. .

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2015, 13 (12) :1481-1497

[9] Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma [J].

Cao, Guoying ;

Ali, Feda' Emad Atta ;

Chiu, Francis ;

Zavascki, Alexandre P. ;

Nation, Roger L. ;

Li, Jian .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (05) :1009-1014

[10]

Cheah SE, 2016, METHOD PHARMACOL TOX, P221, DOI 10.1007/978-1-4939-3323-5_10

← 1 2 3 4 5 6 →